Erste Group Bank Analysts Raise Earnings Estimates for NVO

Novo Nordisk A/S (NYSE:NVO) – Analysts at Erste Group Bank boosted their FY2026 earnings per share (EPS) estimates for shares of Novo Nordisk A/S in a research report issued on Thursday, August 27th. Erste Group Bank analyst H. Engel now forecasts that the company will post earnings of $3.46 per share for the year, up from their previous estimate of $3.27. The consensus estimate for Novo Nordisk A/S’s current full-year earnings is $3.45 per share. Erste Group Bank also issued estimates for Novo Nordisk A/S’s FY2027 earnings at $3.34 EPS.

NVO has been the subject of a number of other reports. Berenberg Bank set a $47.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, August 12th. Weiss Ratings raised shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Wall Street Zen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Finally, HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Four analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $64.94.

Novo Nordisk A/S Trading Down 0.6%

Novo Nordisk A/S stock opened at $45.34 on Monday. The stock has a 50-day moving average price of $48.02 and a 200 day moving average price of $43.83. The company has a market capitalization of $202.44 billion, a price-to-earnings ratio of 11.09, a price-to-earnings-growth ratio of 4.08 and a beta of 0.76. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $64.16. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%.The business had revenue of $11.98 billion for the quarter.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a dividend, which was paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th were issued a $0.5786 dividend. The ex-dividend date of this dividend was Monday, August 17th. This represents a yield of 258.0%. Novo Nordisk A/S’s payout ratio is presently 20.05%.

Institutional Investors Weigh In On Novo Nordisk A/S

Several hedge funds have recently bought and sold shares of the stock. Godfrey Financial Associates Inc. acquired a new position in shares of Novo Nordisk A/S in the 4th quarter valued at $25,000. Transamerica Financial Advisors LLC grew its position in Novo Nordisk A/S by 201.5% during the fourth quarter. Transamerica Financial Advisors LLC now owns 603 shares of the company’s stock valued at $31,000 after buying an additional 403 shares during the period. Johnson Financial Group Inc. grew its position in Novo Nordisk A/S by 128.0% during the third quarter. Johnson Financial Group Inc. now owns 684 shares of the company’s stock valued at $38,000 after buying an additional 384 shares during the period. Scarborough Advisors LLC purchased a new position in Novo Nordisk A/S in the first quarter valued at $26,000. Finally, Continuum Advisory LLC purchased a new position in Novo Nordisk A/S in the second quarter valued at $38,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Share repurchases provide support. Novo Nordisk continued its buyback program, part of a plan to repurchase up to DKK 15 billion over 12 months. The purchases may support earnings per share and signal that management views the valuation as attractive. Novo Nordisk share repurchase programme
• Positive Sentiment: CagriSema remains a potential competitive catalyst. Novo Nordisk’s CagriSema obesity treatment is under U.S. regulatory review, and continued clinical development could broaden the company’s product offering and help close the gap with Eli Lilly in obesity care. Can CagriSema Help Novo Nordisk Close the Gap With LLY in Obesity?
• Neutral Sentiment: Low starter doses may improve treatment tolerability. New research indicates that patients taking low starter doses of GLP-1 weight-loss drugs can still lose weight while experiencing less nausea, although weight loss may be smaller than at recommended doses. The findings could support broader use but do not directly change Novo Nordisk’s near-term outlook. GLP-1 weight loss drugs effective even at low starter doses
• Neutral Sentiment: Analysts remain constructive but cautious. Erste Group issued a fiscal 2026 earnings forecast, while other coverage highlights Novo Nordisk’s Chinese filing, buyback activity and ongoing efforts to compete with Eli Lilly. These developments offer potential upside but do not remove execution and market-share risks. FY2026 Earnings Forecast for NVO Issued By Erste Group Bank
• Negative Sentiment: Competition and clinical concerns continue to weigh on sentiment. The GLP-1 market is becoming more crowded as Eli Lilly and other drugmakers expand their obesity portfolios. Coverage also points to a failed trial and a recent rating downgrade, reinforcing concerns that Novo Nordisk must prove CagriSema can restore its competitive position. Novo Nordisk: Why The Price Remains Stubbornly Low

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.